- Record: found
- Abstract: found
- Article: found
Is Open Access
research-article
Author(s):
Alireza Ghods , PhD 1 ,
Armin Shahrokni , MPH, MD 2 , ,
Hassan Ghasemzadeh , PhD 1 ,
Diane Cook , PhD 1
Publication date (Electronic): 26 November 2021
Journal: JMIR Cancer
Publisher: JMIR Publications
Keywords: step count, performance status, symptom, wearable, activity tracker, gastrointestinal cancer, monitoring, cancer, gastrointestinal, burden
Read this article at
ScienceOpenPublisherPMC
- Review article
- Invite someone to review
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
The number of older patients with gastrointestinal cancer is increasing due to an aging global population. Minimizing reliance on an in-clinic patient performance status test to determine a patient’s prognosis and course of treatment can improve resource utilization. Further, current performance status measurements cannot capture patients' constant changes. These measurements also rely on self-reports, which are subjective and subject to bias. Real-time monitoring of patients' activities may allow for a more accurate assessment of patients’ performance status while minimizing resource utilization. This study investigates the validity of consumer-based activity trackers for monitoring the performance status of patients with gastrointestinal cancer. A total of 27 consenting patients (63% male, median age 58 years) wore a consumer-based activity tracker 7 days before chemotherapy and 14 days after receiving their first treatment. The provider assessed patients using the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scale and Memorial Symptom Assessment Scale-Short Form (MSAS-SF) before and after chemotherapy visits. The statistical correlations between ECOG-PS and MSAS-SF scores and patients’ daily step counts were assessed. The daily step counts yielded the highest correlation with the patients' ECOG-PS scores after chemotherapy ( P<.001). The patients with higher ECOG-PS scores experienced a higher fluctuation in their step counts. The patients who walked more prechemotherapy (mean 6071 steps per day) and postchemotherapy (mean 5930 steps per day) had a lower MSAS-SF score (lower burden of symptoms) compared to patients who walked less prechemotherapy (mean 5205 steps per day) and postchemotherapy (mean 4437 steps per day). Abstract
Background
Objective
Methods
Results
Related collections
Most cited references28
- Record: found
- Abstract: not found
- Article: not found
Toxicity and response criteria of the Eastern Cooperative Oncology Group.
Martin M. Oken, Richard H. Creech, Douglass C. Tormey … (1982)
0 comments Cited 1315 times – based on 0 reviews Review now
Bookmark
- Record: found
- Abstract: found
- Article: not found
Global Burden of 5 Major Types Of Gastrointestinal Cancer
Melina Arnold, Christian C Abnet, Rachel E Neale … (2020)
There were an estimated 4.8 million new cases of gastrointestinal (GI) cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of the global cancer incidence and 35% of all cancer-related deaths. We investigated the global burden from the 5 major GI cancers, as well as geographic and temporal trends in cancer-specific incidence and mortality.
0 comments Cited 578 times – based on 0 reviews Review now
Bookmark
- Record: found
- Abstract: found
- Article: found
Is Open Access
The validity of consumer-level, activity monitors in healthy adults worn in free-living conditions: a cross-sectional study
Ty Ferguson, Alex V Rowlands, Tim Olds … (2015)
Background Technological advances have seen a burgeoning industry for accelerometer-based wearable activity monitors targeted at the consumer market. The purpose of this study was to determine the convergent validity of a selection of consumer-level accelerometer-based activity monitors. Methods 21 healthy adults wore seven consumer-level activity monitors (Fitbit One, Fitbit Zip, Jawbone UP, Misfit Shine, Nike Fuelband, Striiv Smart Pedometer and Withings Pulse) and two research-grade accelerometers/multi-sensor devices (BodyMedia SenseWear, and ActiGraph GT3X+) for 48-hours. Participants went about their daily life in free-living conditions during data collection. The validity of the consumer-level activity monitors relative to the research devices for step count, moderate to vigorous physical activity (MVPA), sleep and total daily energy expenditure (TDEE) was quantified using Bland-Altman analysis, median absolute difference and Pearson’s correlation. Results All consumer-level activity monitors correlated strongly (r > 0.8) with research-grade devices for step count and sleep time, but only moderately-to-strongly for TDEE (r = 0.74-0.81) and MVPA (r = 0.52-0.91). Median absolute differences were generally modest for sleep and steps (<10% of research device mean values for the majority of devices) moderate for TDEE (<30% of research device mean values), and large for MVPA (26-298%). Across the constructs examined, the Fitbit One, Fitbit Zip and Withings Pulse performed most strongly. Conclusions In free-living conditions, the consumer-level activity monitors showed strong validity for the measurement of steps and sleep duration, and moderate valid for measurement of TDEE and MVPA. Validity for each construct ranged widely between devices, with the Fitbit One, Fitbit Zip and Withings Pulse being the strongest performers.
0 comments Cited 192 times – based on 0 reviews Review now
Bookmark
All references
Author and article information
Contributors
Armin Shahrokni:
ORCID: https://orcid.org/0000-0001-9828-9997
Geriatrics / Gastrointestinal Oncology ServiceMemorial Sloan-Kettering Cancer CenterBox 2051275 York AveNew York, NY, 10065United States1 646 888 31811 646 888 3250shahroka@mskcc.org
Journal
Journal ID (nlm-ta): JMIR Cancer
Journal ID (iso-abbrev): JMIR Cancer
Journal ID (publisher-id): JC
Title: JMIR Cancer
Publisher: JMIR Publications (Toronto, Canada )
ISSN (Electronic): 2369-1999
Publication date Collection: Oct-Dec 2021
Publication date (Electronic): 26 November 2021
Volume: 7
Issue: 4
Electronic Location Identifier: e22931
Affiliations
Author notes
Corresponding Author: Armin Shahrokni shahroka@ 123456mskcc.org
Author information
Alireza Ghods https://orcid.org/0000-0002-6343-4573
Armin Shahrokni https://orcid.org/0000-0001-9828-9997
Hassan Ghasemzadeh https://orcid.org/0000-0002-1844-1416
Diane Cook https://orcid.org/0000-0002-4441-7508
Article
Publisher ID: v7i4e22931
DOI: 10.2196/22931
PMC ID: 8665393
PubMed ID: 34842527
SO-VID: d896111d-7d60-4773-af1d-f7cc647643f6
Copyright © ©Alireza Ghods, Armin Shahrokni, Hassan Ghasemzadeh, Diane Cook. Originally published in JMIR Cancer (https://cancer.jmir.org), 26.11.2021.
License:
This is an open-access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on https://cancer.jmir.org/, as well as this copyright and license information must be included.
History
Date received : 27 July 2020
Date revision requested : 18 October 2020
Date revision received : 14 December 2020
Date accepted : 25 September 2021
Categories
Subject: Original Paper
Subject: Original Paper
Keywords: step count,performance status,symptom,wearable,activity tracker,gastrointestinal cancer,monitoring,cancer,gastrointestinal,burden
Data availability:
Keywords: step count, performance status, symptom, wearable, activity tracker, gastrointestinal cancer, monitoring, cancer, gastrointestinal, burden
Comments
Comment on this article
Sign in to comment